Topics Coronavirus Vaccine | Fujifilm Holdings
TOKYO (Reuters) - Fujifilm Holdings Corp said on Wednesday its Avigan drug reduced viral loads and symptoms of COVID-19 patients, paving the way for regulatory approval in Japan after months of delays.
The Phase 3 clinical study of 156 patients showed that those treated with Avigan improved after 11.9 days, versus 14.
7 days for a placebo group. Results of the study, conducted by subsidiary Fujifilm Toyama Chemical, were statistically significant, the company said in a release. Former Japanese Prime Minister Shinzo Abe had touted Avigan's.
This article is no longer available in our repository.
There could be multiple reasons for this.
You could try searching for this headline on the source website (bloomberg.com).